熱門資訊> 正文
Tvardi Therapeutics GAAP每股收益为-1.00美元
2025-08-15 04:58
- Tvardi Therapeutics press release (NASDAQ:TVRD): Q2 GAAP EPS of -$1.00.
- Cash, cash equivalents and short-term investments as of June 30, 2025, were $41.0 million, as compared to $31.6 million as of December 31, 2024.
More on Tvardi Therapeutics
- Historical earnings data for Tvardi Therapeutics
- Financial information for Tvardi Therapeutics
風險及免責提示:以上內容僅代表作者的個人立場和觀點,不代表華盛的任何立場,華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前,應結合自身情況,考慮投資產品的風險。必要時,請諮詢專業投資顧問的意見。華盛不提供任何投資建議,對此亦不做任何承諾和保證。